<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787185</url>
  </required_header>
  <id_info>
    <org_study_id>15901</org_study_id>
    <nct_id>NCT04787185</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiotherapy in Association With Immunotherapy for the Treatment of NSCLC Brain Metastases</brief_title>
  <acronym>STRAITLUC</acronym>
  <official_title>STRAIT-LUC Trial: Stereotactic Radiotherapy (SRT) in Association With Immunotherapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer (NSCLC): a Multicenter Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria Careggi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria Careggi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's primary objective is the evaluation of toxicities reported during RS or HFSRT in&#xD;
      patients with brain metastases from NSCLC undergoing immunotherapy (Safety), with particular&#xD;
      reference to the rate of symptomatic radionecrosis and intralesional hemorrhage. Others&#xD;
      primary objectives of the study are the Feasibility and the intracranial control of the&#xD;
      disease, both local (site radiotherapy treatment) and at a distance (intracranial, but at a&#xD;
      distance from the site of the disease treated with stereotaxic radiotherapy). The secondary&#xD;
      objectives concern quality assessment of life of the patients under study (Quality Of Life,&#xD;
      QoL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who experience grade 3-5 toxicity within 3 months of initiation, graded according to the National Cancer Institute (NCI) CTCAE version (v)4.0</measure>
    <time_frame>24 Months</time_frame>
    <description>Evaluation of toxicity related to the combination of radiotherapy and immunotherapy</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Brain Metastases From NSCLC</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Valutation of toxicity</intervention_name>
    <description>Observation of toxicity&#xD;
All patient with Brain metastases from NSCLC who are candidates for RS or HFSRT in course of immunotherapy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with brain metastasis for NSCLC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years&#xD;
&#xD;
               -  Ability to express informed consent&#xD;
&#xD;
          -  Histological or cytological diagnosis (possibility of PDL-1 determination) of NSCLC&#xD;
&#xD;
          -  - Brain metastases up to a maximum of 10 and all treated with RS or Hypofractionated&#xD;
             stereotactic radiotherapy (3 to 5 fractions)&#xD;
&#xD;
          -  Brain disease assessable according to iRANO criteria&#xD;
&#xD;
          -  Radiation therapy on brain metastases within 4 weeks before or after infusion of&#xD;
             immunotherapy in the following settings&#xD;
&#xD;
          -  brain metastases at initio brain metastases treated with RS + 1st line therapy&#xD;
&#xD;
          -  Brain metastases as I progression after I line of systemic therapy CHT, IT or CHTIT&#xD;
             regardless of whether or not the same line is continued (treatment Beyond progression)&#xD;
             or shift to the next line;&#xD;
&#xD;
          -  Brain metastases as II progression after II line of systemic therapy (CHT, IT)&#xD;
             regardless of whether it is continued or not of the same line (treatment beyond&#xD;
             progression) or shift to the next line.&#xD;
&#xD;
          -  Diagnostic brain MRI for brain metastases within one month of treatment stereotactic&#xD;
&#xD;
        Esclusion criteria:&#xD;
&#xD;
          -  Life expectancy of less than 6 months (calculated with GPA score &lt;2)&#xD;
&#xD;
          -  Performance Status&gt; 2&#xD;
&#xD;
          -  Previous radiotherapy treatment at the brain site&#xD;
&#xD;
          -  Contraindication to MRI of the brain with contrast medium&#xD;
&#xD;
          -  Presence of a number of intracranial metastases&gt; 10&#xD;
&#xD;
          -  Inability to express informed consent&#xD;
&#xD;
          -  Infusion of immunotherapy more than 4 weeks before and after radiotherapy&#xD;
&#xD;
          -  Impossibility of recording times and dosages of administration of steroid therapy&#xD;
&#xD;
          -  Ineligibility for immunotherapy treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radioterapia Oncologica AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Flego, CTF</last_name>
      <phone>00390557947192</phone>
      <email>datamanager.gs.rt@sbsc.unifi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria Careggi</investigator_affiliation>
    <investigator_full_name>Lorenzo Livi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

